| Terrence Roberts, Dds, Llc | |
|
996 W State St # 2 Albany IN 47320-1519 | |
| (765) 729-9212 | |
| Not Available |
| Full Name | Terrence Roberts, Dds, Llc |
|---|---|
| Speciality | Dentist - General Practice |
| Location | 996 W State St # 2, Albany, Indiana |
| Authorized Official Name and Position | Terrence Brandon Roberts (OWNER) |
| Authorized Official Contact | 7657299212 |
| Accepts Medicare Insurance | This clinic does not participate in Medicare Program. |
| Mailing Address | Practice Location Address |
|---|---|
| Terrence Roberts, Dds, Llc 11198 Brookhaven Rd Brookville IN 47012-7304 Ph: (765) 729-9212 | Terrence Roberts, Dds, Llc 996 W State St # 2 Albany IN 47320-1519 Ph: (765) 729-9212 |
| NPI Number | 1134970288 |
|---|---|
| Provider Enumeration Date | 03/28/2024 |
| Last Update Date | 03/28/2024 |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134970288 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1223G0001X | Dentist - General Practice | (* (Not Available)) | Primary |
News Archive
Federal programs to assist the unemployed are failing job seekers with disabilities, according to an investigation by Jean Hall and Kathy Parker of the Center for Research on Learning at the University of Kansas.
Plexxikon Inc. announces that enrollment has been initiated and the first patient has been dosed in a pivotal Phase 3 trial of PLX4032 (RG7204) in patients with metastatic melanoma. PLX4032 is a novel, oral and highly targeted drug that is designed to inhibit the BRAF cancer-causing mutation that occurs in about 50 percent of melanomas and about eight percent of all solid tumors. The randomized, controlled, Phase 3 "BRAF Inhibitor in Melanoma" (BRIM3) trial in previously untreated patients is part of the planned registration program for PLX4032.
The risk of maternal complications and preterm deliveries is significantly higher for women undergoing their fifth or more caesarean section, finds a new study published today (31 October) in BJOG: An International Journal of Obstetrics and Gynaecology.
The American College of Rheumatology joins organizations from around the world in celebrating World Arthritis Day. Held every year on October 12, this year's theme is "Move to Improve" - focusing on using physical activity to combat arthritis and rheumatic diseases - such as osteoarthritis, rheumatoid arthritis, lupus, gout and psoriatic arthritis.
Arrowhead Research Corporation, a targeted therapeutics company, today announced that, through its Calando Pharmaceuticals subsidiary, it has completed enrollment of a phase 1b clinical trial of CALAA-01, its RNAi therapeutic candidate targeting solid tumors. All patients participating in the trial have completed dosing with the exception of one patient who is still receiving treatment and will continue to be monitored.
› Verified 3 days ago